Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Issues FY 2013 Guidance In Line With Analysts' Estimates; Reaffirms FY 2015 Guidance; Issues FY 2017 Guidance


Monday, 7 Jan 2013 11:30am EST 

Celgene Corp announced that for fiscal 2013, it expects net product sales to be approximately $6.0 billion and adjusted diluted earnings per share (EPS) in the range of $5.50 to $5.60. Based on U.S. Generally Accepted Accounting Principles (GAAP), diluted EPS is expected in the range of $4.67 to $4.79. The Company also reaffirmed 2015 targets of $8.0-9.0 billion in net product sales and adjusted diluted EPS of $8.00 to $9.00. The Company also expects fiscal 2017 target of $12.0 billion in net product sales and adjusted diluted EPS of $13.00 to $14.00. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.0 billion and EPS of $5.57 for fiscal 2013; revenue of $8.1 billion and EPS of $8.31 for fiscal 2015. 

Company Quote

89.19
1.36 +1.55%
11 Jul 2014